Literature DB >> 11855972

Development of quantitative structure-activity relationship and classification models for a set of carbonic anhydrase inhibitors.

Brian E Mattioni1, Peter C Jurs.   

Abstract

Mathematical models are developed to find quantitative structure-activity relationships that correlate chemical structure and inhibition toward three carbonic anhydrase (CA) isozymes: CA I, II, and IV. Numerical descriptors are generated to encode important topological, geometric, and electronic features of molecular structure. After descriptor generation, multiple linear regression, and computational neural network (CNN) analyses are performed on various descriptor subsets to find superior models for prediction. Committees of five CNNs were utilized to average final predicted values for the 142-compound data set. For inhibitors of CA I, an 8-5-1 CNN committee produced a training set rms error of 0.105 log K(i) (r(2) = 0.994) and prediction set rms error of 0.208 log K(i) (r(2) = 0.980). Training and prediction set rms errors of 0.140 log K(i) (r(2) = 0.992) and 0.231 log K(i) (r(2) = 0.971), respectively, were produced by a 9-5-1 CNN committee for inhibitors of CA II. For prediction of CA IV inhibitors, an 8-5-1 CNN committee produced training and prediction set rms errors of 0.147 log K(i) (r(2) = 0.992) and 0.211 log K(i) (r(2) = 0.991), respectively. In addition, classification models were built using k-nearest neighbor (kNN) analysis to solve two- and three-class problems for inhibitors of CA IV. A three-descriptor classification model proved superior in labeling compounds as active or inactive inhibitors for the two-class problem. Training and prediction set percent classification rates of 100% and 87.1%, respectively, were obtained. For the three-class (active/moderate/inactive) problem, a five-descriptor model was deemed optimal producing a training set percent classification rate of 98.8% and prediction set rate of 79.0%.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855972     DOI: 10.1021/ci0100696

Source DB:  PubMed          Journal:  J Chem Inf Comput Sci        ISSN: 0095-2338


  7 in total

Review 1.  Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM).

Authors:  Michael Fernandez; Julio Caballero; Leyden Fernandez; Akinori Sarai
Journal:  Mol Divers       Date:  2010-03-20       Impact factor: 2.943

2.  QSAR modeling based on the bias/variance compromise: a harmonious and parsimonious approach.

Authors:  John H Kalivas; Joel B Forrester; Heather A Seipel
Journal:  J Comput Aided Mol Des       Date:  2004 Jul-Sep       Impact factor: 3.686

3.  Quantitative Series Enrichment Analysis (QSEA): a novel procedure for 3D-QSAR analysis.

Authors:  Bernd Wendt; Richard D Cramer
Journal:  J Comput Aided Mol Des       Date:  2008-02-27       Impact factor: 3.686

4.  Probing the opportunities for designing anthelmintic leads by sub-structural topology-based QSAR modelling.

Authors:  Prabodh Ranjan; Mohd Athar; Prakash Chandra Jha; Kari Vijaya Krishna
Journal:  Mol Divers       Date:  2018-04-02       Impact factor: 2.943

5.  Computational modeling of in vitro biological responses on polymethacrylate surfaces.

Authors:  Jayeeta Ghosh; Dan Y Lewitus; Prafulla Chandra; Abraham Joy; Jared Bushman; Doyle Knight; Joachim Kohn
Journal:  Polymer (Guildf)       Date:  2011-05-26       Impact factor: 4.430

Review 6.  Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction.

Authors:  Haiyan Li; Jin Sun; Xiaowen Fan; Xiaofan Sui; Lan Zhang; Yongjun Wang; Zhonggui He
Journal:  J Comput Aided Mol Des       Date:  2008-06-24       Impact factor: 3.686

7.  Developing and validating predictive decision tree models from mining chemical structural fingerprints and high-throughput screening data in PubChem.

Authors:  Lianyi Han; Yanli Wang; Stephen H Bryant
Journal:  BMC Bioinformatics       Date:  2008-09-25       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.